DE10299029I2 - Benzimidazole, diese Verbindungen enthaltende Arzneimittel und Verfahren zu ihrer Herstellung - Google Patents

Benzimidazole, diese Verbindungen enthaltende Arzneimittel und Verfahren zu ihrer Herstellung

Info

Publication number
DE10299029I2
DE10299029I2 DE2002199029 DE10299029C DE10299029I2 DE 10299029 I2 DE10299029 I2 DE 10299029I2 DE 2002199029 DE2002199029 DE 2002199029 DE 10299029 C DE10299029 C DE 10299029C DE 10299029 I2 DE10299029 I2 DE 10299029I2
Authority
DE
Germany
Prior art keywords
benzimidazolyl
alkyl
substd
opt
cooh
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
DE2002199029
Other languages
German (de)
English (en)
Other versions
DE10299029I1 (de
Inventor
Norbert Hauel
Berthold Narr
Uwe Ries
Van Jacques Meel
Wolfgang Wienen
Michael Entzeroth
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Boehringer Ingelheim Pharma GmbH and Co KG
Original Assignee
Dr Karl Thomae GmbH
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=27202166&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=DE10299029(I2) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Priority claimed from DE4103492A external-priority patent/DE4103492A1/de
Application filed by Dr Karl Thomae GmbH filed Critical Dr Karl Thomae GmbH
Application granted granted Critical
Publication of DE10299029I1 publication Critical patent/DE10299029I1/de
Publication of DE10299029I2 publication Critical patent/DE10299029I2/de
Active legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D231/00—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings
    • C07D231/02—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings
    • C07D231/10—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D231/12—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/02—Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/08—Vasodilators for multiple indications
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D233/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings
    • C07D233/54—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members
    • C07D233/56—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members with only hydrogen atoms or radicals containing only hydrogen and carbon atoms, attached to ring carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D235/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, condensed with other rings
    • C07D235/02—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, condensed with other rings condensed with carbocyclic rings or ring systems
    • C07D235/04—Benzimidazoles; Hydrogenated benzimidazoles
    • C07D235/06—Benzimidazoles; Hydrogenated benzimidazoles with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached in position 2
    • C07D235/08—Radicals containing only hydrogen and carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D249/00—Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms
    • C07D249/02—Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms not condensed with other rings
    • C07D249/08—1,2,4-Triazoles; Hydrogenated 1,2,4-triazoles
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/10—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a carbon chain containing aromatic rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D513/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00
    • C07D513/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00 in which the condensed system contains two hetero rings
    • C07D513/04—Ortho-condensed systems

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Urology & Nephrology (AREA)
  • Biomedical Technology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Vascular Medicine (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Endocrinology (AREA)
  • Reproductive Health (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Professional, Industrial, Or Sporting Protective Garments (AREA)
  • Electroluminescent Light Sources (AREA)
  • Polymers With Sulfur, Phosphorus Or Metals In The Main Chain (AREA)
  • Battery Electrode And Active Subsutance (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Low-Molecular Organic Synthesis Reactions Using Catalysts (AREA)
DE2002199029 1991-02-06 1992-01-31 Benzimidazole, diese Verbindungen enthaltende Arzneimittel und Verfahren zu ihrer Herstellung Active DE10299029I2 (de)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
DE4103492A DE4103492A1 (de) 1991-02-06 1991-02-06 Benzimidazole, diese verbindungen enthaltende arzneimittel und verfahren zu ihrer herstellung
DE4117121A DE4117121A1 (de) 1991-02-06 1991-05-25 Benzimidazole, diese verbindungen enthaltende arzneimittel und verfahren zu ihrer herstellung
DE4137812A DE4137812A1 (de) 1991-02-06 1991-11-16 Benzimidazole, diese verbindungen enthaltende arzneimittel und verfahren zu ihrer herstellung

Publications (2)

Publication Number Publication Date
DE10299029I1 DE10299029I1 (de) 2003-01-23
DE10299029I2 true DE10299029I2 (de) 2006-06-29

Family

ID=27202166

Family Applications (2)

Application Number Title Priority Date Filing Date
DE2002199029 Active DE10299029I2 (de) 1991-02-06 1992-01-31 Benzimidazole, diese Verbindungen enthaltende Arzneimittel und Verfahren zu ihrer Herstellung
DE59209330T Expired - Lifetime DE59209330C5 (de) 1991-02-06 1992-01-31 Benzimidazole, diese Verbindungen enthaltende Arzneimittel und Verfahren zu ihrer Herstellung

Family Applications After (1)

Application Number Title Priority Date Filing Date
DE59209330T Expired - Lifetime DE59209330C5 (de) 1991-02-06 1992-01-31 Benzimidazole, diese Verbindungen enthaltende Arzneimittel und Verfahren zu ihrer Herstellung

Country Status (26)

Country Link
EP (1) EP0502314B1 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
JP (1) JP2709225B2 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
AT (1) ATE166346T1 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
BG (1) BG62309B2 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
CA (1) CA2060624C (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
CH (1) CH0502314H1 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
CZ (1) CZ287607B6 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
DE (2) DE10299029I2 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
DK (1) DK0502314T3 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
ES (1) ES2118095T4 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
FI (1) FI105547B (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
HK (1) HK1011145A1 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
HR (1) HRP940752B1 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
HU (2) HU217084B (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
IE (1) IE81111B1 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
IL (1) IL100864A (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
LU (3) LU90372I2 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
MX (1) MX9200509A (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
NL (2) NL990007I2 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
NO (3) NO301585B1 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
NZ (1) NZ241515A (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
PL (1) PL169675B1 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
RU (1) RU2053229C1 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
SG (1) SG50481A1 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
SI (1) SI9210098B (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
SK (1) SK279261B6 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)

Families Citing this family (96)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE4224133A1 (de) * 1992-07-22 1994-01-27 Thomae Gmbh Dr K Benzimidazole, diese Verbindungen enthaltende Arzneimittel und Verfahren zu ihrer Herstellung
DE4224752A1 (de) * 1992-04-11 1994-02-03 Thomae Gmbh Dr K Benzimidazole, diese Verbindungen enthaltende Arzneimittel und Verfahren zu ihrer Herstellung
DE4225756A1 (de) 1992-01-22 1994-03-10 Thomae Gmbh Dr K Benzimidazole, diese Verbindungen enthaltende Arzneimittel und Verfahren zu ihrer Herstellung
TW274551B (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html) * 1991-04-16 1996-04-21 Takeda Pharm Industry Co Ltd
DE4207904A1 (de) * 1992-03-12 1993-09-16 Thomae Gmbh Dr K Substituierte benzimidazolylderivate, diese verbindungen enthaltende arzneimittel und verfahren zu ihrer herstellung
US5972990A (en) † 1992-04-10 1999-10-26 Brigham And Women's Hospital, Inc. Methods for reducing risk of repeat myocardial infarction and increasing survival in heart attack victims
GB9218449D0 (en) 1992-08-29 1992-10-14 Boots Co Plc Therapeutic agents
DE4315349A1 (de) * 1992-10-06 1994-11-10 Thomae Gmbh Dr K Benzimidazole, diese Verbindungen enthaltende Arzneimittel und Verfahren zu ihrer Herstellung
JP3057471B2 (ja) 1993-06-07 2000-06-26 武田薬品工業株式会社 アンジオテンシンｉｉ介在性諸疾患の予防または治療剤
DE4408497A1 (de) * 1994-03-14 1995-09-21 Thomae Gmbh Dr K Benzimidazole, diese Verbindungen enthaltende Arzneimittel und Verfahren zu ihrer Herstellung
JPH11513395A (ja) * 1995-10-06 1999-11-16 ノバルティス・アクチエンゲゼルシャフト 虚血後腎不全の予防および処置並びに虚血腎臓の保護のためのａｔ１−レセプターアンタゴニスト
TW453999B (en) * 1997-06-27 2001-09-11 Fujisawa Pharmaceutical Co Benzimidazole derivatives
HUP0003982A3 (en) * 1997-10-17 2002-01-28 Eurogene Ltd The use of inhibitors of the renin-angiotensin system for producing pharmaceutical compositions using for the treatment of hypoxia or impaired metabolic function
EP1357120A1 (en) * 1998-03-16 2003-10-29 Celgene Corporation 2-(2,6-dioxopiperidin-3-yl)isoindoline derivatives, their preparation and their use as inhibitors of inflammatory cytokines
WO2000027397A1 (en) * 1998-11-06 2000-05-18 Glaxo Group Limited Antihypertensive medicaments containing lacidipine and telmisartan
BR9916576A (pt) 1998-12-23 2001-10-02 Novartis Ag Uso de antagonista receptor at-1 ou modulador receptor at-2 para o tratamento de doenças associadas com um aumento de receptores at-1 ou at-2
EP1013273A1 (en) * 1998-12-23 2000-06-28 Novartis AG Use of AT-1 receptor antagonist or AT-2 receptor modulator for treating diseases associated with an increase of AT-1 or AT-2 receptors
US6358986B1 (en) 1999-01-19 2002-03-19 Boehringer Ingelheim Pharma Kg Polymorphs of telmisartan
DE19901921C2 (de) * 1999-01-19 2001-01-04 Boehringer Ingelheim Pharma Polymorphe von Telmisartan, Verfahren zu deren Herstellung und deren Verwendung zur Herstellung eines Arzneimittels
SE9903028D0 (sv) 1999-08-27 1999-08-27 Astra Ab New use
AR033390A1 (es) 2000-08-22 2003-12-17 Novartis Ag Una composicion farmaceutica que comprende un antagonista del receptor at1 y un potenciador de la secrecion de insulina, el uso de dicha composicion para la fabricacion de un medicamento y un kit de partes
DE10153737A1 (de) * 2001-10-31 2003-05-28 Boehringer Ingelheim Pharma Kristallines Natriumsalz des Telmisartans, Verfahren zu dessen Herstellung und dessen Verwendung zur Herstellung eines Arzneimittels
US6737432B2 (en) 2001-10-31 2004-05-18 Boehringer Ingelheim Pharma Kg Crystalline form of telmisartan sodium
BR0215514A (pt) 2002-01-16 2004-12-21 Boehringer Ingelheim Pharma Comprimido farmacêutico de bicamada compreendendo telmisartan e um diurético e preparação deste
EG24716A (en) 2002-05-17 2010-06-07 Novartis Ag Combination of organic compounds
DE10335027A1 (de) 2003-07-31 2005-02-17 Boehringer Ingelheim Pharma Gmbh & Co. Kg Verwendung von Angiotensin II Rezeptor Antagonisten
DE10306179A1 (de) 2003-02-13 2004-08-26 Boehringer Ingelheim Pharma Gmbh & Co. Kg Verwendung von Dipyridamol in Kombination mit Acetylsalicylsäure und einem Angiotensin II-Antagonisten zur Schlaganfall-Prophylaxe
DE10314702A1 (de) 2003-03-31 2004-10-21 Boehringer Ingelheim Pharma Gmbh & Co. Kg Verfahren zur Herstellung von Telmisartan
DE10319450A1 (de) * 2003-04-30 2004-11-18 Boehringer Ingelheim Pharma Gmbh & Co. Kg Pharmazeutische Formulierung des Telmisartan Natriumsalzes
US9029363B2 (en) 2003-04-30 2015-05-12 Boehringer Ingelheim International Gmbh Telmisartan sodium salt pharmaceutical formulation
DE10319592A1 (de) * 2003-05-02 2004-11-18 Boehringer Ingelheim Pharma Gmbh & Co. Kg Behandlung von diabetischer Retinopathie mit Angiotensin II-Rezeptorblockern
US7732162B2 (en) 2003-05-05 2010-06-08 Probiodrug Ag Inhibitors of glutaminyl cyclase for treating neurodegenerative diseases
GB0316546D0 (en) 2003-07-15 2003-08-20 Novartis Ag Process for the manufacture of organic compounds
RU2422450C2 (ru) 2003-11-19 2011-06-27 Метабазис Терапеутикс, Инк. Новые фосфорсодержащие тиромиметики
GB2414019A (en) * 2004-05-11 2005-11-16 Cipla Ltd One-step preparation of telmisartan by condensation and hydrolysis
CA2581723A1 (en) * 2004-10-15 2006-04-27 Teva Pharmaceutical Industries Ltd. Process for preparing telmisartan
EP1806332A4 (en) 2004-10-27 2010-03-31 Daiichi Sankyo Co Ltd BENZOL CONNECTION WITH TWO OR MORE SUBSIDIARIES
ITMI20050801A1 (it) * 2005-05-03 2006-11-04 Dipharma Spa Procedimento per la preparazione di telmisartan
WO2006136916A2 (en) * 2005-06-20 2006-12-28 Glenmark Pharmaceuticals Limited Substantially pure micronized particles of telmisartan and pharmaceutical compositions containing same
WO2007010558A1 (en) * 2005-07-19 2007-01-25 Matrix Laboratories Limited A process for the preparation of telmisartan
ES2246742B1 (es) * 2005-09-06 2007-02-01 Prous Institute For Biomedical Research S.A. Uso de un derivado de imidazol.
EP1908469A1 (en) 2006-10-06 2008-04-09 Boehringer Ingelheim Vetmedica Gmbh Angiotensin II receptor antagonist for the treatment of systemic diseases in cats
KR101126383B1 (ko) 2007-02-07 2012-04-12 교와 핫꼬 기린 가부시키가이샤 3환계 화합물
FR2916757B1 (fr) * 2007-05-30 2009-07-17 Servier Lab Nouveaux derives diazeniumdiolates,leur procede de preparation et les compositions pharmaceutiques qui les contiennent.
CN103601792B (zh) 2007-06-04 2016-06-29 协同医药品公司 有效用于胃肠功能紊乱、炎症、癌症和其他疾病治疗的鸟苷酸环化酶激动剂
US8969514B2 (en) 2007-06-04 2015-03-03 Synergy Pharmaceuticals, Inc. Agonists of guanylate cyclase useful for the treatment of hypercholesterolemia, atherosclerosis, coronary heart disease, gallstone, obesity and other cardiovascular diseases
TWI406850B (zh) * 2007-06-05 2013-09-01 Theravance Inc 雙效苯并咪唑抗高血壓劑
CN101743228B (zh) * 2007-07-03 2014-01-29 新梅斯托克尔卡托瓦纳兹德拉韦尔公司 替米沙坦的制备方法
WO2009076288A1 (en) * 2007-12-11 2009-06-18 Theravance, Inc. Dual-acting benzoimidazole derivative and their use as antihypertensive agents
EP2103609A1 (en) 2008-03-20 2009-09-23 Lek Pharmaceuticals D.D. Catalyzed carbonylation in the synthesis of angiotensin ii antagonists
CN102015690B (zh) * 2008-03-20 2014-04-30 力奇制药公司 血管紧张素ii拮抗剂合成中的催化羧化
EP2103588A1 (en) 2008-03-20 2009-09-23 Lek Pharmaceuticals D.D. 2'-Halobiphenyl-4-yl intermediates in the synthesis of angiotensin II antagonists
WO2009123483A1 (en) 2008-03-31 2009-10-08 Zaklady Farmaceutyczne Polpharma Sa Process for preparation of telmisartan
EP2291177A2 (en) 2008-05-05 2011-03-09 Farmaprojects, S.A. Stable pharmaceutical compositions and their processes for preparation suitable for industrial scale
EP2123648A1 (en) 2008-05-20 2009-11-25 Chemo Ibérica, S.A. A process for the preparation of Telmisartan.
CA2726917C (en) 2008-06-04 2018-06-26 Synergy Pharmaceuticals Inc. Agonists of guanylate cyclase useful for the treatment of gastrointestinal disorders, inflammation, cancer and other disorders
WO2010004385A1 (en) * 2008-06-17 2010-01-14 Aurobindo Pharma Limited Process for the preparation of pure 4'-[4-methyl-6-(1-methyl-2-benzimidazolyl)-2-propyl-1-benzimidazolyl]methyl]-2-biphenylcarboxylic acid
EP2149566A1 (en) 2008-07-15 2010-02-03 Chemo Ibérica, S.A. A process for the preparation of telmisartan
EP2321341B1 (en) 2008-07-16 2017-02-22 Synergy Pharmaceuticals Inc. Agonists of guanylate cyclase useful for the treatment of gastrointestinal, inflammation, cancer and other disorders
EP3081213B1 (en) 2008-08-06 2020-04-01 Kyowa Kirin Co., Ltd. Tricyclic compound
WO2010093601A1 (en) 2009-02-10 2010-08-19 Metabasis Therapeutics, Inc. Novel sulfonic acid-containing thyromimetics, and methods for their use
PL2443094T3 (pl) 2009-06-19 2013-08-30 Krka Tovarna Zdravil D D Novo Mesto Sposób wytwarzania telmisartanu
EP2277866A1 (en) 2009-06-22 2011-01-26 Inke, S.A. Process for preparing telmisartan
EP2448575A2 (en) 2009-07-02 2012-05-09 Bilgic Mahmut Pharmaceutical composition increasing solubility and stability
WO2011002423A2 (en) 2009-07-02 2011-01-06 Mahmut Bilgic Solubility enhancing pharmaceutical composition
TR200906506A2 (tr) 2009-08-24 2011-03-21 Bi̇lgi̇ç Mahmut Telmisartan içeren katı dozaj formları.
EP2305650A1 (en) 2009-09-21 2011-04-06 Chemo Ibérica, S.A. Novel process for the preparation of telmisartan
CN101798300B (zh) * 2010-02-23 2013-09-25 陈志龙 N-苯基吲哚甲基取代的双苯并咪唑衍生物及其降压等应用
EP2575808A1 (en) 2010-05-28 2013-04-10 Mahmut Bilgic Combination of antihypertensive agents
WO2011161123A2 (en) 2010-06-21 2011-12-29 Krka, Tovarna Zdravil, D.D., Novo Mesto Multilayer pharmaceutical tablet comprising telmisartan and a diuretic
US9616097B2 (en) 2010-09-15 2017-04-11 Synergy Pharmaceuticals, Inc. Formulations of guanylate cyclase C agonists and methods of use
WO2012055941A1 (en) 2010-10-27 2012-05-03 Krka,Tovarna Zdravil, D. D., Novo Mesto Multilayer pharmaceutical composition comprising telmisartan and amlodipine
WO2013030725A1 (en) 2011-08-26 2013-03-07 Wockhardt Limited Methods for treating cardiovascular disorders
EP2612658A1 (en) 2012-01-05 2013-07-10 Laboratorios Lesvi, S.L. Pharmaceutical compositions of 4'-[(1,4'dimethyl-2'-propyl[2,6'-bi-1h-benzimidazol]-1'-yl)methyl]-[1,1'-biphenyl]-2-carboxylic acid and is 6-chloro-3,4-dihydro-2h-1,2,4-benzothiadiazine-7-sulfonamide-1,1-dioxide
US9486494B2 (en) 2013-03-15 2016-11-08 Synergy Pharmaceuticals, Inc. Compositions useful for the treatment of gastrointestinal disorders
CA2905438A1 (en) 2013-03-15 2014-09-25 Synergy Pharmaceuticals Inc. Agonists of guanylate cyclase and their uses
SI3004138T1 (sl) 2013-06-05 2024-07-31 Bausch Health Ireland Limited Ultra čisti agonisti gvanilat ciklaze C, postopek za njihovo pripravo in uporabo
ES2661437T3 (es) 2013-06-21 2018-04-02 Zenith Epigenetics Corp. Nuevos compuestos bicíclicos sustituidos como inhibidores de bromodominio
SG10201710705UA (en) * 2013-06-21 2018-02-27 Zenith Epigenetics Ltd Novel bicyclic bromodomain inhibitors
KR20160038008A (ko) 2013-07-31 2016-04-06 제니쓰 에피제네틱스 코포레이션 브로모도메인 억제제로서 신규 퀴나졸리논
EP2979691A1 (en) 2014-07-30 2016-02-03 Boehringer Ingelheim International GmbH Oral disintegrating tablet
EP3227281A4 (en) 2014-12-01 2018-05-30 Zenith Epigenetics Ltd. Substituted pyridinones as bromodomain inhibitors
US10292968B2 (en) 2014-12-11 2019-05-21 Zenith Epigenetics Ltd. Substituted heterocycles as bromodomain inhibitors
HK1245247A1 (zh) 2014-12-17 2018-08-24 恒翼生物医药科技(上海)有限公司 溴结构域的抑制剂
JP5871294B1 (ja) 2015-02-27 2016-03-01 ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング 即時放出経口錠剤
KR20170001921A (ko) 2015-06-26 2017-01-05 대원제약주식회사 안정성이 개선된 텔미사르탄을 함유하는 약제학적 조성물 및 이의 제조방법
KR20170012703A (ko) 2015-07-22 2017-02-03 대원제약주식회사 텔미사르탄을 함유하는 약제학적 조성물 및 이의 제조방법
EP3463309B1 (en) 2016-05-30 2020-06-17 Boehringer Ingelheim International GmbH Fixed dose combination of telmisartan, hydrochlorothiazide and amlodipine
KR101872726B1 (ko) 2016-07-28 2018-06-29 주식회사 씨트리 텔미사르탄 메탄술폰산염 및 이를 포함하는 약제학적 조성물
FI3648761T3 (fi) 2017-07-07 2024-05-21 Boehringer Ingelheim Vetmedica Gmbh Telmisartaani kissan hypertension ehkäisemiseksi tai hoitamiseksi
AU2019241702B2 (en) 2018-03-30 2023-07-27 Orizuru Therapeutics, Inc Heterocyclic compound
WO2023001880A1 (en) 2021-07-22 2023-01-26 Krka, D. D., Novo Mesto Bilayer tablet comprising telmisartan and indapamide
CN118265545A (zh) * 2021-10-04 2024-06-28 博尔特生物治疗药物有限公司 不对称双苯并咪唑sting激动剂免疫缀合物及其用途
WO2024240633A1 (en) 2023-05-24 2024-11-28 Boehringer Ingelheim Vetmedica Gmbh Combination treatment and/or prevention of renal diseases and/or hypertension in non-human mammals comprising one or more sglt-2 inhibitors and telmisartan
TW202508593A (zh) 2023-05-24 2025-03-01 德商百靈佳殷格翰維美迪加股份有限公司 包含一或多種sglt-2抑制劑及匹莫苯坦(pimobendan)及/或替米沙坦(telmisartan)之非人類哺乳動物心臟病之組合治療及/或預防
WO2025125409A1 (en) 2023-12-15 2025-06-19 Boehringer Ingelheim Vetmedica Gmbh Angiotensin ii receptor antagonist for the prevention of systemic diseases in cats

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4880804A (en) * 1988-01-07 1989-11-14 E. I. Du Pont De Nemours And Company Angiotensin II receptor blocking benzimidazoles
DE3928177A1 (de) * 1989-04-08 1991-02-28 Thomae Gmbh Dr K Benzimidazole, diese verbindungen enthaltende arzneimittel und verfahren zu ihrer herstellung
EP0400835A1 (en) * 1989-05-15 1990-12-05 Merck & Co. Inc. Substituted benzimidazoles as angiotensin II antagonists
IE64514B1 (en) * 1989-05-23 1995-08-09 Zeneca Ltd Azaindenes
GB8911854D0 (en) * 1989-05-23 1989-07-12 Ici Plc Heterocyclic compounds
IL94390A (en) * 1989-05-30 1996-03-31 Merck & Co Inc The 6-membered trans-nitrogen-containing heterocycles are compressed with imidazo and pharmaceutical preparations containing them
IE70593B1 (en) * 1989-09-29 1996-12-11 Eisai Co Ltd Biphenylmethane derivative the use of it and pharmacological compositions containing same
US5196444A (en) * 1990-04-27 1993-03-23 Takeda Chemical Industries, Ltd. 1-(cyclohexyloxycarbonyloxy)ethyl 2-ethoxy-1-[[2'-(1H-tetrazol-5-yl)biphenyl-4-yl]methyl]benzimidazole-7-carboxylate and compositions and methods of pharmaceutical use thereof
RU1836357C (ru) * 1990-07-23 1993-08-23 Др.Карл Томэ ГмбХ Производные бензимидазола, их изомеры, смеси изомеров, гидраты или их физиологически переносимые соли, обладающие антагонистическими в отношении ангиотензина свойствами

Also Published As

Publication number Publication date
PL293387A1 (en) 1993-01-25
SI9210098A (en) 1994-12-31
LU91802I2 (fr) 2011-05-30
CZ287607B6 (cs) 2001-01-17
SG50481A1 (en) 1998-07-20
EP0502314B1 (de) 1998-05-20
CA2060624A1 (en) 1992-08-07
EP0502314A1 (de) 1992-09-09
ES2118095T4 (es) 2011-04-07
NO2002011I2 (no) 2008-03-03
HU9200355D0 (en) 1992-04-28
HRP940752A2 (en) 1997-04-30
FI920486L (fi) 1992-08-07
LU90950I2 (fr) 2002-10-30
PL169675B1 (pl) 1996-08-30
IE920373A1 (en) 1992-08-12
CA2060624C (en) 1999-12-21
NO920476L (no) 1992-08-07
NZ241515A (en) 1994-10-26
IL100864A (en) 1996-01-19
DE59209330C5 (de) 2013-10-31
IL100864A0 (en) 1992-11-15
FI920486A0 (fi) 1992-02-05
NL300095I1 (nl) 2002-09-02
AU1070792A (en) 1992-08-13
NL300095I2 (nl) 2002-11-01
NO301585B1 (no) 1997-11-17
HUT60493A (en) 1992-09-28
JP2709225B2 (ja) 1998-02-04
NO920476D0 (no) 1992-02-05
DE10299029I1 (de) 2003-01-23
NL990007I2 (nl) 1999-07-01
NO2011005I1 (no) 2011-05-16
SK279261B6 (sk) 1998-08-05
DK0502314T3 (da) 1999-03-29
CS30692A3 (en) 1992-08-12
AU655794B2 (en) 1995-01-12
HU217084B (hu) 1999-11-29
JPH04346978A (ja) 1992-12-02
HRP940752B1 (en) 2001-02-28
CH0502314H1 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html) 2012-03-15
HU211524A9 (en) 1995-11-28
HK1011145A1 (en) 1999-07-02
ES2118095T3 (es) 1998-09-16
DE59209330D1 (de) 1998-06-25
SI9210098B (sl) 2000-06-30
ATE166346T1 (de) 1998-06-15
RU2053229C1 (ru) 1996-01-27
FI105547B (fi) 2000-09-15
NL990007I1 (nl) 1999-06-01
IE81111B1 (en) 2000-03-08
MX9200509A (es) 1992-08-01
BG62309B2 (bg) 1999-07-30
LU90372I2 (fr) 1999-05-12

Similar Documents

Publication Publication Date Title
DE10299029I2 (de) Benzimidazole, diese Verbindungen enthaltende Arzneimittel und Verfahren zu ihrer Herstellung
ATE18910T1 (de) Succinimid-derivate und verfahren zu ihrer herstellung.
DK0497659T3 (da) Aryl-(eller heteroaryl)-piperazinyl-alkyl-azolderivater, deres fremstilling samt deres anvendelse som lægemidler
NO177008C (no) Analogifremgangsmåte for fremstilling av terapeutisk aktive tiazolidinon-derivater
KR920701167A (ko) 약제학적 활성 화합물
CA2413000A1 (en) Five-membered ring compounds
KR880007540A (ko) 2β-치환-메틸페니실란산 유도체 및 그의염 및 에스테르
FI94639C (fi) Menetelmä terapeuttisesti käyttökelpoisten aryylitiatsolyylimetyyli-imidatsolien valmistamiseksi
KR890005054A (ko) 치료제로서 유용한 4-아릴-5-카바모일-1, 4-디하이드로피리딘
ES8800175A1 (es) Procedimiento para la obtencion de derivados de acido 5-(azoli-loxifenilcarbamoil)-barbiturico.
AU615385B2 (en) Heterocyclicgaunidines as 5ht antagonists
IE812944L (en) Pyrazoline derivatives
KR940009186A (ko) 이미다조피리딘
KR870010043A (ko) 헤테로고리로 치환된 벤즈이미다졸, 그의 제조방법 및 이들을 함유하는 제약조성물
ATE90680T1 (de) Heterocyclisch substituierte 5,7-dihydropyrrolo(3,2-f>benzoxazol-6-one, verfahren zu ihrer herstellung sowie diese verbindungen enthaltende arzneimittel.
GB1249512A (en) 0,2,3,4-tetrahydro-7-halo-6-sulfamyl-4-quinazolinones, process for preparing the same and pharmaceutical compositions comprising the same
ATE154603T1 (de) Heterozyklische säuren
NO950484L (no) 3- og 5-substituerte 1,2,3,4-oksatriazol-5-iminforbindelser, fremgangsmåte for fremstilling derav, farmasöytisk preparat inneholdende forbindelsene samt anvendelse av slike for fremstilling av medikamenter